The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 11 of the 68 sources its claims cite were checked for support.
KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Open accessAbstract
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with significant public health concerns. This review examines the landscape of KRAS inhibition in colorectal cancer (CRC), focusing on recent advances in therapeutic strategies targeting this oncogene. Historically deemed undruggable due to its complex structure and essential role in tumorigenesis, KRAS mutations are prevalent in CRC and are associated with poor prognosis. However, breakthroughs in drug development have led to the emergence of KRAS inhibitors as promising treatment options. This review discusses various classes of KRAS inhibitors, including covalent and non-covalent inhibitors, as well as combination therapies aimed at enhancing efficacy and overcoming resistance mechanisms. It highlights recent clinical trials evaluating the efficacy of KRAS inhibitors either as monotherapy or in combination with other agents, such as anti-EGFR antibodies. Despite challenges such as resistance mechanisms and tumor heterogeneity, the development of KRAS inhibitors represents a significant advance in CRC treatment and holds promise for improving patient outcomes in the future.
Overview
CoChat Summary
TL;DR
This review summarizes KRAS inhibition strategies in colorectal cancer, including covalent and non-covalent mutation-specific inhibitors, pan-KRAS inhibitors, indirect inhibitors, and combination approaches to overcome resistance. It reports early clinical efficacy for KRAS G12C inhibitors alone and with anti-EGFR antibodies, while emphasizing remaining resistance and the need for further trials.
Key findings
- KRAS mutations occur in approximately 40–50% of colorectal cancers; common codon 12 mutations G12D and G12V account for about 28% and 19% of KRAS mutations in CRC, respectively, and G13D for 17%, while codon 61 mutations account for approximately 5–10%.
- In KRAS G12C-mutant CRC, adagrasib monotherapy produced an objective response rate of 23%, disease control rate of 86%, median progression-free survival of 5.6 months, median overall survival of 19.8 months, and grade 3–4 toxicities in 34% (n = 43); sotorasib monotherapy produced an objective response rate of 9.7%, disease control rate of 82.3%, median progression-free survival of 4.0 months, median overall survival of 10.6 months, and grade 3–4 toxicities in 10% (n = 62).
- Combining KRAS G12C inhibitors with anti-EGFR antibodies increased activity: sotorasib plus panitumumab had an objective response rate of 30% versus 10% for sotorasib monotherapy, and the phase III combination arm had progression-free survival of 5.6 months; adagrasib plus cetuximab was associated with a 46% response rate, median response duration of 7.6 months, and median progression-free survival of 6.9 months.
- Preclinically, MRTX1133 showed approximately 700-fold higher selectivity for KRAS G12D over wild-type KRAS and induced tumor regression of 30% or more in 11 of 25 KRAS G12D mutant models, including 8 of 11 pancreatic cancer models.
Methods
- Narrative review synthesizing preclinical and clinical studies on KRAS signaling and KRAS-targeted therapies in colorectal cancer; no systematic review search strategy or meta-analysis is described.
- Data include published literature, early-phase through phase III clinical trials, and tables of safety/efficacy for KRAS G12C inhibitors in CRC and ongoing clinical trials.
- Main analysis is a qualitative synthesis of mechanisms, resistance pathways, drug classes, and combination strategies.
Limitations
- The paper states that challenges remain in addressing resistance mechanisms and optimizing therapeutic regimens to maximize efficacy while minimizing toxicity; further clinical studies are warranted to validate emerging therapies, explore optimal combinations, and identify predictive biomarkers.
- Evident from the text: as a narrative review, it does not report a systematic search, inclusion criteria, or risk-of-bias assessment; many cited data are from early-phase trials or preclinical models, and CRC-specific data are limited for some strategies such as pan-KRAS inhibitors, vaccines, and CAR-T cells.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 KRAS mutations prevalence in solid tumors and CRC. (A) Percentage of KRAS alterations (tumors with prevalence > 10%), according to the GENIE cohort v13.0-public (red: colorectum) [4]. (B) KRAS mutation prevalence in CRC (from [1]).](https://figures.cochat.ai/paper-figures/24ab1786e3d64dd69d04e0d7a8d70c8e/kras-a-new-target-for-precision-medicine-in-colorectal-cancer-figure-2.jpg)
![Figure 3 Mechanisms of bypassing KRAS inhibitors through the activation of wild-type (WT) forms of RAS (NRAS and HRAS) [29,31] (biorender).](https://figures.cochat.ai/paper-figures/2ffdfe8143ab4a46a6ef7a6f67d713d0/kras-a-new-target-for-precision-medicine-in-colorectal-cancer-figure-3.jpg)

Verification
Claims the paper makes
6 Valid · 0 Not valid · 43 Not checked · 14 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, KRAS mutant CRC harbors a boosted glucose metabolism as well as deregulation of glutamine, amino-acid, and fatty acid metabolism that support cancer cell proliferation [48].”
§ KRAS, a New Target for Precision Medicine in Colorectal Cancer? > 4. Other Strategies to Target KRAS > 4.2. Other Therapeutic Class
What the sources say
- Supportedcites [48] 2020, Metabolic Pathways Regulating Colorectal Cancer Initiation and Progression, Semin. Cell Dev. Biol. source
Section 2.2 (p. 3) states that KRAS boosts glucose metabolism and regulates glutamine, amino-acid, and fatty-acid metabolism to support cancer cell proliferation. The same passage describes increased glucose uptake and other metabolic changes in KRAS-mutant CRC. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although initial data from studies on adagrasib or sotorasib monotherapy [10,11] are promising in patients with KRASG12C mutations, reactivation may occur in the RAS-MAPK signaling pathway due to a feedback loop mediated by the epidermal growth factor receptor (EGFR) [29,30] (Figure 3).”
§ KRAS, a New Target for Precision Medicine in Colorectal Cancer? > 3. KRAS Inhibition: KRAS G12C > 3.2. Combination with Other Drugs
What the sources say
- Supportedcites [29] Ryan, 2022, KRASG12C-Independent Feedback Activation of Wild-Type RAS Constrains KRASG12C Inhibitor Efficacy, Cell Rep. source
The Introduction (page unavailable) reports that EGFR inhibition can abrogate adaptive RAS-MAPK feedback reactivation during KRASG12C inhibition. The Discussion (page unavailable) identifies EGFR as a major driver of adaptive resistance in KRASG12C colorectal cancer, while noting that other receptors can also drive reactivation. That supports the claim’s qualified wording that EGFR-mediated reactivation may occur. (LLM, conf=0.90)
- Supportedcites [30] Amodio, 2020, EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer, Cancer Discov. source
The Introduction (p. 4) says EGFR reactivation restricts the efficacy of KRAS G12C inhibition in colorectal cancer models. The Discussion (p. 9) reports an EGFR–MAPK signaling rebound after KRAS G12C inhibition, supporting the proposed feedback mechanism. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several drugs targeting KRAS indirectly are currently in development by interfering with nucleotide exchange and KRAS activation via SHP2 or SOS1 inhibition [54,55,56,57,58].”
§ KRAS, a New Target for Precision Medicine in Colorectal Cancer? > 4. Other Strategies to Target KRAS > 4.2. Other Therapeutic Class
What the sources say
- Not checked yetcites [54] Ladumor, 2020, NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma, Cancer Res. source
- Supportedcites [55] Sheffels, E., and Kortum, R.L. (2021). The Role of Wild-Type RAS in Oncogenic RAS Transformation. Genes, 12. source
Section 4.4 describes the development of specific SHP2 and SOS1 inhibitors as new approaches to treating RAS-mutated cancers. It links their activity to RAS nucleotide cycling, while the cited SOS1-inhibitor work is described as blocking RAS activation. The claim is a fair broad paraphrase, though the section notes that effectiveness depends on the mutation and treatment context; no page number is available in our copy. (LLM, conf=0.89)
- Partly supportedcites [56] Nichols, 2018, RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven Cancers, Nat. Cell Biol. sourceExperimental — accuracy not yet measured
The Abstract reports that the SHP2 inhibitor RMC-4550 reduces RAS signaling by disrupting SOS1-mediated RAS-GTP loading. The Results section reports that SOS1 knockdown had similar effects, but the paper does not establish that several drugs, including SOS1 inhibitors, were in development. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Supportedcites [57] Hofmann, 2021, BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition, Cancer Discov. source
The Introduction says SHP2 inhibitors are in phase 1 trials and links SHP2 to SOS1-regulated RAS-GTP loading. The Discussion describes the SOS1 inhibitor BI-3406 as blocking the SOS1–KRAS interaction and reducing RAS-GTP levels. Together, these passages support the claim that drugs targeting KRAS indirectly through SHP2 or SOS1 inhibition are in development; page numbers are not available in our copy. (LLM, conf=0.90)
- Not checked yetcites [58] Zhao, 2021, Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors, Cancer Discov. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“MRTX1133 induced tumor regression of 30% or more in 11 out of 25 KRASG12D mutant models (PDX or cell lines) [39].”
§ KRAS, a New Target for Precision Medicine in Colorectal Cancer? > 4. Other Strategies to Target KRAS > 4.1. Other Codon Specific Inhibitor: MRTX1133 (KRASG12D)
What the sources say
- Not checked yetcites [39] (2022). The KRASG12D Inhibitor MRTX1133 Elucidates KRAS-Mediated Oncogenesis. Nat. Med., 28, 2017–2018. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Notably, wild-type RAS isoforms, including HRAS and NRAS, but not the oncogenic KRAS, transmit downstream signaling from activated EGFR, resulting in rebound signaling of RAS effectors and reduced efficacy of MRTX1133.”
§ KRAS, a New Target for Precision Medicine in Colorectal Cancer? > 4. Other Strategies to Target KRAS > 4.1. Other Codon Specific Inhibitor: MRTX1133 (KRASG12D)
What the sources say
- Not checked yetcites [31] Feng, 2023, Feedback Activation of EGFR/Wild-Type RAS Signaling Axis Limits KRASG12D Inhibitor Efficacy in KRASG12D-Mutated Colorectal Cancer, Oncogene source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
25 more claims
Create a free account to see all 63 claims and to verify the 57 references still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, there are several limitations, such as standardization, assay performance, economic feasibility, limited tumor shedding, restricted access to the bloodstream, and false negatives due to low shedding [10,83,84].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ KRAS, a New Target for Precision Medicine in Colorectal Cancer? > 4. Other Strategies to Target KRAS > 4.2. Other Therapeutic Class
“The pan-RAS strategy adopted by Boehringer Ingelheim® focuses on inhibitors of the switch I/II pocket, such as the compound BI-2865 [51,52].”
§ KRAS, a New Target for Precision Medicine in Colorectal Cancer? > 4. Other Strategies to Target KRAS > 4.2. Other Therapeutic Class
“This non-covalent inhibitor preferentially binds to and with high affinity to the inactive state of KRAS while preserving NRAS and HRAS HRAS [52].”
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 1×
“Key types of KRAS mutations found in CRC are [19,20]: ERK is then translocated into the nucleus where it activates the transcription of target genes.”
BackgroundTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Cited by
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 20
“Clinically, KRAS mutations are associated with poor prognosis, resistance to anti-EGFR monoclonal antibodies (like cetuximab and panitumumab), and limited therapeutic options, making this a challenging subset of CRC to treat [3,6,8].”
Song, W., Wang, Y., Zhou, M., Guo, F., & Liu, Y. (2025) · Human Genomics · doi:10.1186/s40246-025-00805-x · Cited by 14
Sharma, P., Pal, D., Gill, A. R., Gupta, M., Goyal, S., Bansal, P., Sharma, U., Mathkor, D. M., Haque, S., Kaur, D., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02587-z · Cited by 8
KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
Emami, A., Sharif, P. M., & Rezaei, N. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2500426 · Cited by 4
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Abukhadra, M. R., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1808601 · Cited by 3
“A notable design feature of NCT05578092 is the requirement for baseline and on-treatment tumor biopsies for pharmacodynamic evaluation when medically feasible, supporting a rigorous linkage between drug exposure and pathway modulation in humans (Dillon et al., 2021; Sudhakar et al., 2024).”
Influential
Metadata
- Authors
- Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., Mathieu, J. R. R., Jaulin, F., Hollebecque, A., & Ducreux, M.
- Affiliations
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Université Paris-Saclay (FR)
- Corresponding author
- Boilève, Alice
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-10-12
- Volume
- 16
- Issue
- 20
- Pages
- 3455
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11506008
- OpenAlex
- W4403400820
- Semantic Scholar
- fb2b2b3e1404460dc6b1af8ba825f6d6ab2d5a2a
- Cited by
- 11
- References
- 64
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 1
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Research Agency (ANR-21-RHUS-0003)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS, colorectal cancer, KRAS inhibitors, precision medicine, covalent inhibitors, non-covalent inhibitors, combination therapy, anti-EGFR monoclonal antibody, drug resistance, tumor heterogeneity, KRAS mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRAS, a New Target for Precision Medicine in Colorectal Cancer? https://app.cochat.ai/papers/10.3390/cancers16203455
- The paper
- Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., Mathieu, J. R. R., Jaulin, F., Hollebecque, A., & Ducreux, M. (2024). KRAS, a New Target for Precision Medicine in Colorectal Cancer? Cancers. https://doi.org/10.3390/cancers16203455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.